BioSpaceOriginal article
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
Data ReadoutpositiveDT120Positive
AI Analysis
Summary
Definium Therapeutics reported positive topline results from a second consecutive study of DT120 (LSD) for generalized anxiety disorder, with analysts indicating the drug is moving toward FDA submission.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Positive topline results from second straight study in generalized anxiety disorder
Importance:7/10
Sentiment:
0.85
clinical trialFDA submissiongeneralized anxiety disorderpsychedelicsPhase 2
Read the original article
Published by BioSpace on September 14, 2026 1:42 PM